8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Feb 23, 2026·SEC
Material company update
Dec 8, 2025·SEC
Arcellx, Inc.(ACLX)Earnings, Financials & Key Ratios
ACLX•NASDAQ
Price updated May 29, 2026
AboutArcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.Show more
- Revenue$22M-79.4%
- EBITDA-$246M-86.1%
- Net Income-$229M-113.3%
- EPS (Diluted)-4.07-103.5%
- Gross Margin70.03%-26.4%
- EBITDA Margin-1105.65%-801.5%
- Operating Margin-1135.61%-791.0%
- Net Margin-1027.25%-932.9%
- ROE-53.42%-133.9%
ACLX Key Insights
Arcellx, Inc. (ACLX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 81 (top 19%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Profits declining 48.1% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Expensive at 16.1x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ACLX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ACLX Price & Volume
Arcellx, Inc. (ACLX) stock price & volume — 10-year historical chart
Loading chart...
ACLX Growth Metrics
Arcellx, Inc. (ACLX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-79.35%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-113.26%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-101.99%
Return on Capital
10 Years-57.76%
5 Years-53.56%
3 Years-28.85%
Last Year-46.62%
ACLX Recent Earnings
Arcellx, Inc. (ACLX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 3/12 qtrs (25%)
Q1 2026Latest
Feb 26, 2026Metric
Actual
Est
EPS
$1.01+0.0%
$1.01
Rev
$4M-65.0%
$13M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.99-3.1%
$0.96
Rev
$5M-60.9%
$13M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.94+8.7%
$1.03
Rev
$8M-44.9%
$14M
Q2 2025
May 8, 2025Metric
Actual
Est
EPS
$1.13-34.5%
$0.84
Rev
$8M-36.8%
$13M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $1.01vs $1.01+0.0% | $4Mvs $13M-65.0% |
| Q4 2025 | Nov 5, 2025 | $0.99vs $0.96-3.1% | $5Mvs $13M-60.9% |
| Q3 2025 | Aug 7, 2025 | $0.94vs $1.03+8.7% | $8Mvs $14M-44.9% |
| Q2 2025 | May 8, 2025 | $1.13vs $0.84-34.5% | $8Mvs $13M-36.8% |
Based on last 12 quarters of dataView full earnings history →
ACLX Peer Comparison
Arcellx, Inc. (ACLX) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LEGN | 5.17B | 27.93 | -17.46 | 64.04% | -21.97% | -24.91% | 0.41 | |
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 ALLO | 487.74M | 2.00 | -2.30 | -100% | -56.45% | 0.26 | ||
 AUTL | 401.88M | 1.51 | -1.40 | 6.47% | -311.95% | -128.53% | 1.97 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 |
Compare ACLX vs Peers
Arcellx, Inc. (ACLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ACLX Income Statement
Arcellx, Inc. (ACLX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 110.32M | 107.94M | 22.29M |
Revenue Growth % | - | - | - | - | - | - | -2.16% | -79.35% |
Cost of Goods Sold | 0 | 326K | 0 | 0 | 2.22M | 0 | 5.19M | 6.68M |
COGS % of Revenue | - | - | - | - | - | - | 4.81% | 29.97% |
Gross Profit | 0▲ 0% | -326K▲ 0% | 0▲ 100.0% | 0▲ 0% | -2.22M▲ 0% | 110.32M▲ 5060.4% | 102.75M▼ 6.9% | 15.61M▼ 84.8% |
Gross Margin % | - | - | - | - | - | 100% | 95.19% | 70.03% |
Gross Profit Growth % | - | - | 100% | - | - | 5060.39% | -6.86% | -84.81% |
Operating Expenses | 8.31M | 17.97M | 32.1M | 65.02M | 189.03M | 200.2M | 240.32M | 268.69M |
OpEx % of Revenue | - | - | - | - | - | 181.47% | 222.65% | 1205.65% |
Selling, General & Admin | 2.2M | 2.21M | 7.04M | 18.14M | 41.7M | 66.35M | 88.41M | 117.76M |
SG&A % of Revenue | - | - | - | - | - | 60.14% | 81.91% | 528.39% |
Research & Development | 6.11M | 15.77M | 25.06M | 46.88M | 149.56M | 133.85M | 157.09M | 157.61M |
R&D % of Revenue | - | - | - | - | - | 121.33% | 145.54% | 707.22% |
Other Operating Expenses | 0 | 0 | -1 | 0 | -2.22M | 0 | -5.19M | -6.68M |
Operating Income | -8.31M▲ 0% | -17.97M▼ 116.3% | -32.1M▼ 78.6% | -65.02M▼ 102.6% | -191.26M▼ 194.2% | -89.88M▲ 53.0% | -137.57M▼ 53.1% | -253.08M▼ 84.0% |
Operating Margin % | - | - | - | - | - | -81.47% | -127.46% | -1135.61% |
Operating Income Growth % | - | -116.32% | -78.57% | -102.57% | -194.16% | 53.01% | -53.06% | -83.97% |
EBITDA | -8.22M | -17.65M | -31.47M | -63.98M | -189.03M | -87.84M | -132.38M | -246.41M |
EBITDA Margin % | - | - | - | - | - | -79.62% | -122.65% | -1105.65% |
EBITDA Growth % | - | -114.8% | -78.3% | -103.31% | -195.47% | 53.53% | -50.71% | -86.13% |
D&A (Non-Cash Add-back) | 93K | 326K | 629K | 1.04M | 2.22M | 2.04M | 5.19M | 6.68M |
EBIT | -8.31M | -17.97M | -32.1M | -64.96M | -186.96M | -66.19M | -104.25M | -204.65M |
Net Interest Income | 0 | 0 | 1K | 290K | 2.58M | 19.85M | 32.29M | -24.22M |
Interest Income | 0 | 0 | 1K | 300K | 4.3M | 23.7M | 33.32M | 0 |
Interest Expense | 0 | 0 | 0 | 10K | 1.72M | 3.84M | 1.03M | 24.22M |
Other Income/Expense | 999 | 2K | 999 | 49K | 2.58M | 19.85M | 32.29M | 24.22M |
Pretax Income | -8.31M▲ 0% | -17.97M▼ 116.3% | -32.09M▼ 78.6% | -64.97M▼ 102.4% | -188.68M▼ 190.4% | -70.03M▲ 62.9% | -105.28M▼ 50.3% | -228.87M▼ 117.4% |
Pretax Margin % | - | - | - | - | - | -63.48% | -97.54% | -1026.95% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 663K | 2.07M | 69K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | -0.95% | -1.97% | -0.03% |
Net Income | -8.31M▲ 0% | -17.97M▼ 116.3% | -32.09M▼ 78.6% | -64.97M▼ 102.4% | -188.68M▼ 190.4% | -70.69M▲ 62.5% | -107.35M▼ 51.9% | -228.93M▼ 113.3% |
Net Margin % | - | - | - | - | - | -64.08% | -99.46% | -1027.25% |
Net Income Growth % | - | -116.32% | -78.58% | -102.43% | -190.41% | 62.53% | -51.86% | -113.26% |
Net Income (Continuing) | -8.31M | -17.97M | -32.09M | -64.97M | -188.68M | -70.69M | -107.35M | -228.93M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -50.17▲ 0% | -0.52▲ 99.0% | -1.47▼ 182.7% | -1.94▼ 32.0% | -4.28▼ 120.6% | -1.47▲ 65.7% | -2.00▼ 36.1% | -4.07▼ 103.5% |
EPS Growth % | - | 98.96% | -182.69% | -31.97% | -120.62% | 65.65% | -36.05% | -103.5% |
EPS (Basic) | -50.17 | -0.52 | -1.47 | -1.94 | -4.28 | -1.47 | -2.00 | -4.07 |
Diluted Shares Outstanding | 165.58K | 34.78M | 21.78M | 33.54M | 44.11M | 48.06M | 53.57M | 56.31M |
Basic Shares Outstanding | 165.58K | 34.78M | 21.78M | 33.54M | 44.11M | 48.06M | 53.57M | 56.31M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
ACLX Balance Sheet
Arcellx, Inc. (ACLX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 14.63M | 38.07M | 49.36M | 112.81M | 266.86M | 716.36M | 599.31M | 462.18M |
Cash & Short-Term Investments | 14.53M | 34.58M | 46.6M | 104.62M | 254.84M | 702.02M | 587.38M | 450.33M |
Cash Only | 14.53M | 34.58M | 46.6M | 30.83M | 64.18M | 394.58M | 105.68M | 80.26M |
Short-Term Investments | 0 | 0 | 0 | 73.78M | 190.66M | 307.43M | 481.7M | 370.07M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.6M |
Days Sales Outstanding | - | - | - | - | - | - | - | 58.96 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 99K | 621K | 1.21M | 2.05M | 3.67M | 7.58M | 6.05M | 8.25M |
Total Non-Current Assets | 1.18M | 5.52M | 8.34M | 15.97M | 46.95M | 108.77M | 112.02M | 141.81M |
Property, Plant & Equipment | 817K | 4.33M | 4.9M | 10.32M | 39.89M | 69.83M | 70.25M | 0 |
Fixed Asset Turnover | - | - | - | - | - | 1.58x | 1.54x | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 199K | 0 | 0 | 27.17M | 38.28M | 72.33M |
Other Non-Current Assets | 366K | 1.19M | 3.24M | 5.66M | 7.06M | 11.77M | 3.5M | 69.47M |
Total Assets | 15.81M▲ 0% | 43.59M▲ 175.7% | 57.69M▲ 32.4% | 128.78M▲ 123.2% | 313.82M▲ 143.7% | 825.13M▲ 162.9% | 711.33M▼ 13.8% | 603.99M▼ 15.1% |
Asset Turnover | - | - | - | - | - | 0.13x | 0.15x | 0.04x |
Asset Growth % | - | 175.66% | 32.36% | 123.22% | 143.68% | 162.93% | -13.79% | -15.09% |
Total Current Liabilities | 1.82M | 3.04M | 5.27M | 14.85M | 56.69M | 118.24M | 125.41M | 104.2M |
Accounts Payable | 1.05M | 1.75M | 504K | 1.33M | 9.05M | 2.62M | 2.1M | 5.58M |
Days Payables Outstanding | - | 1.95K | - | - | 1.49K | - | 147.39 | 304.77 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.58M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 50.53M | 59.06M | 0 |
Other Current Liabilities | 766K | 1.05M | 3.4M | 5.58M | 8.48M | 13.74M | 18.97M | 91.05M |
Current Ratio | 8.06x | 12.53x | 9.36x | 7.60x | 4.71x | 6.06x | 4.78x | 4.44x |
Quick Ratio | 8.06x | 12.53x | 9.36x | 7.60x | 4.71x | 6.06x | 4.78x | 4.44x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 73.29M | 1.88M | 235.45M | 52.17M | 221.51M | 131.13M | 97.44M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 44.34M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 52.17M | 50.84M | 46.54M | 44.34M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 73.29M | 1.88M | 235.45M | 0 | 0 | 8.59M | -44.34M |
Total Liabilities | 1.82M | 76.33M | 7.15M | 250.3M | 108.86M | 339.75M | 256.54M | 201.64M |
Total Debt | 0 | 0 | 0 | 0 | 88.13M | 97.63M | 54.08M | 96.26M |
Net Debt | -14.53M | -34.58M | -46.6M | -30.83M | 23.95M | -296.96M | -51.6M | 16M |
Debt / Equity | - | - | - | - | 0.43x | 0.20x | 0.12x | 0.24x |
Debt / EBITDA | - | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - | - |
Interest Coverage | - | - | - | -6495.90x | -108.70x | -17.23x | -101.21x | -8.45x |
Total Equity | 13.96M▲ 0% | -32.74M▼ 334.5% | 50.54M▲ 254.4% | -121.52M▼ 340.4% | 204.95M▲ 268.7% | 485.38M▲ 136.8% | 454.79M▼ 6.3% | 402.35M▼ 11.5% |
Equity Growth % | - | -334.53% | 254.38% | -340.43% | 268.67% | 136.82% | -6.3% | -11.53% |
Book Value per Share | 84.30 | -0.94 | 2.32 | -3.62 | 4.65 | 10.10 | 8.49 | 7.15 |
Total Shareholders' Equity | 13.96M | -32.74M | 50.54M | -121.52M | 204.95M | 485.38M | 454.79M | 402.35M |
Common Stock | 1K | 1K | 2K | 1K | 44K | 52K | 53K | 56K |
Retained Earnings | -15.07M | -33.05M | -65.14M | -130.11M | -318.79M | -389.48M | -496.83M | -725.76M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | -20K | -221K | 547K | 848K | 843K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ACLX Cash Flow Statement
Arcellx, Inc. (ACLX) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -6.86M | -18.77M | -28.66M | -54.24M | -99.3M | 207.57M | -83.47M | -210.26M |
Operating CF Margin % | - | - | - | - | - | 188.16% | -77.33% | -943.45% |
Operating CF Growth % | - | -173.6% | -52.68% | -89.23% | -83.09% | 309.03% | -140.21% | -151.91% |
Net Income | -8.31M | -17.97M | -32.09M | -64.97M | -188.68M | -70.69M | -107.35M | -228.93M |
Depreciation & Amortization | 93K | 326K | 629K | 1.04M | 1.32M | 2.04M | 5.19M | -1.76M |
Stock-Based Compensation | 66K | 136K | 1.05M | 6.75M | 21.54M | 41.79M | 61.09M | 77.89M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 856K | 0 | 0 | 213K | 62.06M | 9.01M | -11.62M | 44K |
Working Capital Changes | 432K | -1.26M | 1.75M | 2.72M | 4.45M | 225.43M | -30.78M | -57.49M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 688K | -1.33M | 974K | 7.42M | -6.47M | -70K | 2.66M |
Cash from Investing | -479K | -3.83M | -888K | -79.98M | -117.67M | -154.51M | -183.04M | 86.3M |
Capital Expenditures | -479K | -3.83M | -888K | -5.78M | -2.28M | -21.43M | -13.43M | -2.33M |
CapEx % of Revenue | - | - | - | - | - | 19.42% | 12.45% | 10.44% |
Acquisitions | 0 | 0 | 0 | 0 | 115.4M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | -115.4M | 0 | 0 | 0 |
Cash from Financing | 12.48M | 42.65M | 41.66M | 118.45M | 252.63M | 279.16M | -24.09M | 98.53M |
Debt Issued (Net) | 0 | 0 | 0 | -387K | -9.68M | -29.39M | -39.85M | -230K |
Equity Issued (Net) | 0 | 42.57M | 42.8M | 119.09M | 259.83M | 299.71M | 15.76M | 137.19M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -24K | 0 | 0 | 0 | 0 |
Other Financing | 12.48M | 86K | -1.15M | -256K | 2.47M | 8.85M | 0 | -38.42M |
Net Change in Cash | 5.14M▲ 0% | 20.05M▲ 290.1% | 12.11M▼ 39.6% | -15.76M▼ 230.2% | 35.65M▲ 326.1% | 332.22M▲ 832.0% | -290.6M▼ 187.5% | -25.43M▲ 91.3% |
Free Cash Flow | -7.34M▲ 0% | -22.6M▼ 208.0% | -29.55M▼ 30.7% | -60.02M▼ 103.1% | -101.58M▼ 69.2% | 186.15M▲ 283.2% | -96.9M▼ 152.1% | -212.59M▼ 119.4% |
FCF Margin % | - | - | - | - | - | 168.73% | -89.78% | -953.89% |
FCF Growth % | - | -207.96% | -30.73% | -103.12% | -69.24% | 283.25% | -152.06% | -119.38% |
FCF per Share | -44.33 | -0.65 | -1.36 | -1.79 | -2.30 | 3.87 | -1.81 | -3.78 |
FCF Conversion (FCF/Net Income) | 0.83x | 1.04x | 0.89x | 0.83x | 0.53x | -2.94x | 0.78x | 0.92x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 212K | 1.64M | 0 |
ACLX Key Ratios
Arcellx, Inc. (ACLX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -59.52% | - | -360.56% | - | -452.26% | -20.48% | -22.84% | -53.42% |
Return on Invested Capital (ROIC) | - | - | - | - | -374.73% | -32.31% | -34.88% | -46.21% |
Gross Margin | - | - | - | - | - | 100% | 95.19% | 70.03% |
Net Margin | - | - | - | - | - | -64.08% | -99.46% | -1027.25% |
Debt / Equity | - | - | - | - | 0.43x | 0.20x | 0.12x | 0.24x |
Interest Coverage | - | - | - | -6495.90x | -108.70x | -17.23x | -101.21x | -8.45x |
FCF Conversion | 0.83x | 1.04x | 0.89x | 0.83x | 0.53x | -2.94x | 0.78x | 0.92x |
Revenue Growth | - | - | - | - | - | - | -2.16% | -79.35% |
Related:ACLX Dividend History·ACLX Revenue History·ACLX Price History·ACLX P/E History·ACLX Financial Ratios·ACLX Institutional Holders
ACLX SEC Filings & Documents
Arcellx, Inc. (ACLX) SEC filings — annual & quarterly reports (10-K, 10-Q)
ACLX Frequently Asked Questions
Arcellx, Inc. (ACLX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Arcellx, Inc. (ACLX) reported $22.3M in revenue for fiscal year 2025.
Arcellx, Inc. (ACLX) saw revenue decline by 79.4% over the past year.
Arcellx, Inc. (ACLX) reported a net loss of $228.9M for fiscal year 2025.
Dividend & Returns
Arcellx, Inc. (ACLX) has a return on equity (ROE) of -53.4%. Negative ROE indicates the company is unprofitable.
Arcellx, Inc. (ACLX) had negative free cash flow of $212.6M in fiscal year 2025, likely due to heavy capital investments.